-
公开(公告)号：US10729818B2
公开(公告)日：2020-08-04
申请号：US15588475
申请日：2017-05-05
Inventor： Arturo J. Vegas , Joshua C. Doloff , Omid Veiseh , Minglin Ma , Robert S. Langer , Daniel G. Anderson
IPC: A61L29/08 , A61K47/36 , A61K9/48 , A61K35/39 , C08B37/00 , A61K9/00 , A61K9/50 , A61L31/10 , A61L33/08 , C07D487/04 , C12N5/00 , C12N5/071
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
-
公开(公告)号：US20200080106A1
公开(公告)日：2020-03-12
申请号：US16432177
申请日：2019-06-05
Applicant: Massachusetts Institute of Technology
Inventor： Daniel G. Anderson , Robert Alexander Wesselhoeft , Piotr S. Kowalski
Abstract: Disclosed are methods and constructs for engineering circular RNA. Disclosed is a vector for making circular RNA, said vector comprising the following elements operably connected to each other and arranged in the following sequence: a.) a 5′ homology arm, b.) a 3′ group I intron fragment containing a 3′ splice site dinucleotide, c.) optionally, a 5′ spacer sequence, d.) a protein coding or noncoding region, e.) optionally, a 3′ spacer sequence, f) a 5′ Group I intron fragment containing a 5′ splice site dinucleotide, and g.) a 3′ homology arm, said vector allowing production of a circular RNA that is translatable or biologically active inside eukaryotic cells. In another embodiment, the vector can comprise the 5′ spacer sequence, but not the 3′ spacer sequence. In yet another embodiment, the vector can comprise the 3′ spacer sequence, but not the 5′ spacer sequence. Also disclosed is a method for purifying the circular RNA produced by the vector and the use of nucleoside modifications in circular RNA produced by the vector.
-
公开(公告)号：US20190254975A1
公开(公告)日：2019-08-22
申请号：US16403183
申请日：2019-05-03
Inventor： Daniel G. Anderson , Robert S. Langer , Tram T. Dang
IPC: A61K9/16 , C12N5/071 , A61L27/54 , A61K31/573 , A61K45/06 , A61K35/39 , G01N33/50 , A61L27/38 , A61K9/00 , A61L27/52 , A61L27/48
Abstract: A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
24.发明申请公开(公告)号：US20190210976A1
公开(公告)日：2019-07-11
申请号：US16091330
申请日：2017-04-04
Applicant: Massachusetts Institute of Technology
Inventor： Shady Farah , Joshua C. Doloff , Robert S. Langer , Daniel G. Anderson
IPC: C07D239/49 , A61P29/00 , A61K9/00
CPC classification number: C07D239/49 , A61K9/0024 , A61K31/404 , A61K31/416 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/496 , A61K31/5025 , A61K31/519 , A61K31/5377 , A61K31/551 , A61K31/553 , A61P29/00 , C07B2200/13
Abstract: The present invention provides, in certain embodiments, compositions comprising a uniform population of free, single crystals of a hydrophobic compound. Methods of administering, and processes for preparing, compositions comprising a uniform population of free, single crystals of a hydrophobic compound are also provided.
-
公开(公告)号：US20190091139A1
公开(公告)日：2019-03-28
申请号：US16200334
申请日：2018-11-26
Inventor： Minglin Ma , Daniel G. Anderson , Robert S. Langer , Omid Veiseh , Joshua Charles Doloff , Delai Chen , Christian J. Kastrup , Arturo Jose Vegas
Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
Patent Agency Ranking
公开(公告)号：US20190046690A9
公开(公告)日：2019-02-14
申请号：US15341118
申请日：2016-11-02
Inventor： Arturo J. Vegas , Joshua C. Doloff , Omid Veiseh , Robert S. Langer , Daniel G. Anderson
Abstract: Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
-
公开(公告)号：US20190002869A1
公开(公告)日：2019-01-03
申请号：US16029273
申请日：2018-07-06
Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Inventor： Hao Yin , Wen Xue , Daniel G. Anderson , Joseph R. Dorkin , Tyler E. Jacks
Abstract: The present disclosure relates to compositions and methods for modifying a gene sequence, and for systems for delivering such compositions. For example, the disclosure relates to modifying a gene sequence using a CRISPR-Cas9 or other nucleic acid editing system, and methods and delivery systems for achieving such gene modification, such as viral or non-viral delivery systems.
-
公开(公告)号：US20180353650A1
公开(公告)日：2018-12-13
申请号：US16007922
申请日：2018-06-13
Inventor： Suman Bose , Volkan Yesilyurt , Lisa Rae Volpatti , Robert S. Langer , Daniel G. Anderson
CPC classification number: A61L27/3834 , A61K9/0024 , A61L27/16 , A61L27/34 , A61L27/38 , A61L27/52 , A61L29/041 , A61L31/048 , C08F20/18 , C08F2438/01 , C08L33/26 , C08L2203/02
Abstract: Macrodevices containing a micro-fabricated body having at least one or multiple compartments and a porous membrane, methods of making and using thereof, are described. The one or multiple compartments encapsulate one or more cells that secrete a therapeutic agent in cell-based therapy. The porous membrane provides immunoprotection the encapsulated cells. Further, the surface of the macrodevices is chemically modified using polymers and/or small molecules, reducing fibrosis of the macrodevices, thereby allowing in vivo delivery of the secreted therapeutic agents for extended periods of time.
-
公开(公告)号：US20180353643A1
公开(公告)日：2018-12-13
申请号：US15573926
申请日：2016-05-17
Inventor： Minglin Ma , Daniel G. Anderson , Robert S. Langer , Omid Veiseh , Arturo Jose Vegas , Joshua Charles Doloff , Delai Chen , Christian J. Kastrup
CPC classification number: A61L27/20 , A61F2/02 , A61F2230/0071 , A61F2240/001 , A61F2250/0068 , A61L27/3804 , A61L27/52 , A61L27/54 , A61L2300/64 , A61L2400/18 , A61M31/002 , A61M2205/04 , A61M2207/00
Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
公开(公告)号：US10047355B2
公开(公告)日：2018-08-14
申请号：US15374227
申请日：2016-12-09
Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Inventor： Hao Yin , Wen Xue , Daniel G. Anderson , Joseph R. Dorkin , Tyler E. Jacks
Abstract: The present disclosure relates to compositions and methods for modifying a gene sequence, and for systems for delivering such compositions. For example, the disclosure relates to modifying a gene sequence using a CRISPR-Cas9 or other nucleic acid editing system, and methods and delivery systems for achieving such gene modification, such as viral or non-viral delivery systems.
-
-
-
-
-
-
-
-
-
Search Results
104
records
(took 0.059 seconds)
